An Early Phase 1 interventional study of FIT-(BCMA+CD19)-CAR-T Cells in Autoimmune Diseases, sponsored by Beijing Boren Hospital. Withdrawn at 1 site in China. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2026-10-15.
Sponsored by Beijing Boren Hospital · Early Phase 1, Interventional, and Treatment
No participants
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 125 studies in Autoimmune Diseases with a site in China — 72 open to participants now, 78 under way, 7 of them phase 3. Autoimmune Diseases · China.
Among the 125 studies in Autoimmune Diseases with a site in China, this one is the 107th largest by enrollment of the 113 interventional ones that give a count, is one of 32 that started in 2025, is one of 57 in phase 1, and was the 119th registered.
804 studies on the registry are indexed under Autoimmune Diseases; 273 are open to participants now.
Browse Autoimmune Diseases studies →72 of the 125 studies in Autoimmune Diseases with a site in China are open now. Recruiting first, the newest first:
Antengene Biologics Limited · Sites in China
Ages 18+
Novartis Pharmaceuticals · Sites in China, United States, Australia and 17 more countries
Ages 18+
Peking University Third Hospital · Sites in China
Ages 18+
Vivacta Biotechnology (Shanghai) Co., Ltd. · Sites in China
Ages 18–65
The Children's Hospital of Zhejiang University School of Medicine · Sites in China
Ages 3+
A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →
Of the 195 Autoimmune Diseases studies recruiting now, 90 (46%) set no upper age limit and 79 (41%) stop at 75 or younger; 55 take children under 18; 36 take healthy volunteers.
This study: 18 Years to 70 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
125 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 68 · Phase 2 20 · Phase 3 10 · Phase 4 5
First in 2008; this study’s year is marked. 32 started in 2025.
By drug class, each counting the studies that test any of its medicines:
Median enrollment 30 across the 113 interventional studies, 850 across the 12 observational. Of the 20 that completed or were terminated, 3 (15%) have results posted.
This tab as a report to print or save as PDF → With an account.
46 of 125 have an industry lead sponsor. The 10 most frequent:
Beijing Boren Hospital is the lead sponsor of 24 studies on the registry; 1 is open to participants now.
Beijing Boren Hospital has 5 studies filed under Autoimmune Diseases — fewer than ten, so there is no comparison to draw.
23 of the studies in Autoimmune Diseases with a site in China that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05925803Phase 3AstraZenecaDetermine Effectiveness of Anifrolumab In SYstemic Sclerosis (DAISY) | 2027-01-06 |
| NCT07470151Union Hospital, Tongji Medical College, Huazhong University of Science and TechnologyClinical Study of EVM18001 in the Treatment of Refractory Autoimmune Diseases | 2026-11 |
| NCT06318533YANRU WANGA Clinical Study of CAR NK Cells for the Treatment of Relapsed/Refractory B-cell Related Autoimmune Diseases | 2026-12-13 |
| NCT06340490Guangdong Ruishun Biotech Co., LtdA Study of RJMty19 in Refractory Systemic Lupus Erythematosus (SLE) | 2026-12-31 |
| NCT06243159Shanxi Bethune HospitalJY231(Internal Clinical Drug Code) Injection for the Treatment of Refractory Autoimmune Diseases | 2026-12-31 |
Add all 23 to your calendar (.ics) → With an account.
Among the 125 studies in Autoimmune Diseases with a site in China, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This study is a single-center, open-label, single-dose exploration clinical trial for treating patients with partially relapsed/refractory autoimmune diseases by infusing FIT-(BCMA+CD19)-CAR-T cells after pre-treatment with cleansing therapy.
In this study phase, a traditional "3+3" trial design is employed for dose escalation.
This study intends to include some patients with relapsed/refractory autoimmune diseases. The subjects will undergo single infusion of FIT-(BCMA+CD19)-CAR-T cells after undergoing screening, collection of peripheral blood mononuclear cells (PBMC), and pre-treatment with conditioning chemotherapy. Apart from the baseline period, the time points for evaluating the therapeutic efficacy of the subjects after treatment are the 1st、2nd、3rd、6th、9th and 12th month after infusion, until disease progression (PD), relapse, change of treatment regimen, death, intolerable toxicity, at the discretion of the investigator, or voluntary withdrawal by the patient (whichever occurs first).
Toxicity will be evaluated according to the Common Terminology Criteria for Adverse Events (CTCAE, version 5.0). Safety of FIT-(BCMA+CD19)-CAR-T cell therapy will be evaluated through laboratory tests, 12-lead electrocardiograms, vital signs, physical examinations, etc. Blood samples will be collected from subjects to assess cellular pharmacokinetics and explore the effects of cellular drugs on ferritin, C-reactive protein, and related cytokines.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Laboratory parameters at screening must meet the following requirements, with no receipt of cell growth factors within 7 days (or 2 weeks for long-acting formulations) prior to the screening hematology assessment:
≥ 1.0 × 10⁹/L. ≥ 60 g/L (without red blood cell transfusion within 14 days). count ≥ 50 × 10⁹/L (thrombocytopenia due to disease may be excluded at the investigator's discretion).
Absolute lymphocyte count (ALC) ≥ 0.5 × 10⁹/L. Serum total ≤ 1.5 × (ULN). (AST) and alanine aminotransferase (ALT) ≤ 2.5 × ULN (acute elevations due to autoimmune disease may be excluded at the investigator's discretion).
(Cockcroft-Gault formula) ≥ 30 mL/min.
Exclusion Criteria:
Prior or concomitant medication:
Prior use of any CAR-T cell product or other genetically modified T-cell therapy.
History of CD19-targeted therapy. Receipt of within 4 weeks before enrollment. Use of another medicinal product within 30 days before screening.
Receipt of biologic macromolecular drugs (e.g., rituximab, belimumab, telitacicept, adalimumab, etanercept, etc.) that have therapeutic effects on the target indication within 4 weeks or 5 half-lives before enrollment.
Receipt of > 20 mg/day of prednisone or equivalent doses of other within 2 weeks before enrollment.
Receipt of conventional synthetic disease-modifying drugs (e.g., cyclophosphamide, methotrexate, leflunomide, sulfasalazine, etc.) that have therapeutic effects on the target indication within 2 weeks before enrollment.
Specific Inclusion/Exclusion Criteria
Systemic Lupus Erythematosus (SLE)
Meet the 2019 European League Against Rheumatism/American College of Rheumatology (EULAR/ACR) classification criteria for SLE.
Disease activity score (SLEDAI-2000) ≥ 6 and at least one British Isles Lupus Assessment Group (BILAG-2004) category A (severe manifestation) or two category B (moderate manifestation) organ scores, or both; OR SLEDAI-2000 ≥ 8.
Definition of relapsed/refractory: persistent disease activity despite conventional therapy for more than 6 months, or recurrence of disease activity after remission. Conventional therapy is defined as the use of corticosteroids and cyclophosphamide, plus any one or more of the following immunomodulatory drugs: antimalarials, azathioprine, mycophenolate mofetil, methotrexate, leflunomide, tacrolimus, cyclosporine, and biologics including rituximab, belimumab, telitacicept, etc.
Relapsed/Refractory Sjögren's Syndrome
Meet the 2002 AECG criteria or the 2016 ACR/EULAR classification criteria for primary Sjögren's syndrome.
Disease activity score (ESSDAI) ≥ 6.
Positive anti-SSA/Ro antibody.
Definition of relapsed/refractory: persistent disease activity despite conventional therapy for more than 6 months, or recurrence of disease activity after remission. Conventional therapy is defined as the use of corticosteroids and cyclophosphamide, plus any one or more of the following immunomodulatory drugs: antimalarials, azathioprine, mycophenolate mofetil, methotrexate, leflunomide, tacrolimus, cyclosporine, and biologics including rituximab, belimumab, telitacicept, etc.
Relapsed/Refractory/Progressive Diffuse Scleroderma
Meet the 2013 ACR classification criteria for scleroderma.
Positive scleroderma-associated antibodies.
Diffuse cutaneous sclerosis manifestations or active interstitial lung disease (ground-glass opacities on HRCT).
Definition of relapsed/refractory: persistent disease activity despite conventional therapy for more than 6 months, or recurrence of disease activity after remission. Conventional therapy is defined as the use of corticosteroids and cyclophosphamide, plus any one or more of the following immunomodulatory drugs: antimalarials, azathioprine, mycophenolate mofetil, methotrexate, leflunomide, tacrolimus, cyclosporine, and biologics including rituximab, belimumab, telitacicept, etc.
Definition of progressive: rapid skin progression (increase in mRSS > 25%); or progression of lung disease (FVC reduction ≥ 10%, or FVC reduction > 5% accompanied by DLCO reduction ≥ 15%).
Note: Fulfillment of either criterion 4 or criterion 5 is sufficient.
Relapsed/Refractory/Progressive Inflammatory Myopathy
Meet the 2017 EULAR/ACR classification criteria for inflammatory myopathy (including DM, PM, ASS, and NM).
Positive myositis antibodies.
For patients with muscle involvement: MMT-8 score \< 142 and at least two of the following five core set measures are abnormal (PhGA, PtGA, or extra-muscular disease activity score ≥ 2; total HAQ score ≥ 0.25; muscle enzyme levels ≥ 1.5 times the ); OR MMT-8 score ≥ 142 but with active interstitial lung disease (ground-glass opacities on HRCT).
Definition of relapsed/refractory: persistent disease activity despite conventional therapy for more than 6 months, or recurrence of disease activity after remission. Conventional therapy is defined as the use of corticosteroids and cyclophosphamide, plus any one or more of the following immunomodulatory drugs: antimalarials, azathioprine, mycophenolate mofetil, methotrexate, leflunomide, tacrolimus, cyclosporine, and biologics including rituximab, belimumab, telitacicept, etc.
Definition of progressive: rapidly progressive interstitial pneumonia within a short period of time.
Note: Fulfillment of either criterion 4 or criterion 5 is sufficient.
Relapsed/Refractory ANCA-Associated Vasculitis
Meet the 2022 ACR/EULAR diagnostic criteria for ANCA-associated vasculitis, including microscopic polyangiitis, granulomatosis with polyangiitis, and eosinophilic granulomatosis with polyangiitis.
Positive ANCA-associated antibodies (MPO-ANCA or PR3-ANCA positive).
Birmingham Vasculitis Activity Score (BVAS) ≥ 15 (total score 63), indicating active vasculitis.
BVAS assessment must include at least one major item, at least three minor items, or at least two renal items (hematuria and proteinuria).
Definition of relapsed/refractory: persistent disease activity despite conventional therapy for more than 6 months, or recurrence of disease activity after remission. Conventional therapy is defined as the use of corticosteroids and cyclophosphamide, plus any one or more of the following immunomodulatory drugs: antimalarials, azathioprine, mycophenolate mofetil, methotrexate, leflunomide, tacrolimus, cyclosporine, and biologics including rituximab, belimumab, telitacicept, etc.
Relapsed/Refractory/Catastrophic Antiphospholipid Syndrome
Meet the 2006 Sydney revised diagnostic criteria for primary antiphospholipid syndrome.
Positive medium-to-high titer antiphospholipid antibodies (IgG/IgM of LA, β2GP1, or aCL), with positivity detected more than twice within 12 weeks.
Definition of relapsed/refractory: recurrent thrombosis despite standard treatment with warfarin or alternative vitamin K antagonists (i.e., within therapeutic range) or standard therapeutic dose low molecular weight heparin (LMWH), and prior use of corticosteroids and cyclophosphamide.
Catastrophic antiphospholipid syndrome must meet all four of the following criteria: (1) involvement of three or more organs, systems, and/or tissues; (2) onset of symptoms within one week; (3) histological confirmation of small vessel occlusion in at least one organ or tissue; (4) positive aPL.
Note: Fulfillment of either criterion 3 or criterion 4 is sufficient.
Relapsed/Refractory Autoimmune Hemolytic Anemia
Meet the diagnostic criteria of the Chinese Guidelines for the Diagnosis and Treatment of Autoimmune Hemolytic Anemia in Adults (2023 Edition).
(i) level meeting the criteria for anemia; (ii) decreased serum haptoglobin (\< 250 mg/L), elevated total (≥ 17.1 μmol/L, predominantly unconjugated bilirubin), elevated lactate dehydrogenase, and reticulocyte percentage > 4% or absolute reticulocyte count > 120 × 10⁹/L; (iii) detection of red blood cell autoantibodies.
Definition of relapsed/refractory: failure, intolerance, or to at least 3 months of therapy with corticosteroids in combination with at least one (cyclophosphamide, azathioprine, vinca alkaloids, calcineurin inhibitors, mycophenolate mofetil) and/or rituximab ( therapy for patients with corticosteroid resistance, relapse, intolerance, dependence, or contraindications: rituximab), with persistent anemia and hemolytic symptoms of varying degrees, and laboratory findings not meeting partial remission criteria (HGB increase > 20 g/L, or HGB normalized but hemolytic biochemical parameters not fully normalized [including reticulocytes, haptoglobin, bilirubin, and lactate dehydrogenase], and transfusion-free for at least 7 days); OR achievement of complete remission (disappearance of clinical symptoms, normalization of red blood cell count, hemoglobin level, reticulocyte percentage, serum bilirubin level, and negative direct and indirect Coombs test) after the above therapy but relapse during maintenance therapy or after drug discontinuation.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.
Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.
“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Absolute neutrophil count (ANC)
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Creatinine clearance (CrCl)
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
LVEF (left ventricular ejection fraction)
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Live vaccines
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Relapsed and refractory
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
INR, PT and aPTT (clotting tests)
Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.
Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Line of therapy
A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.
“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
FIT-(BCMA+CD19)-CAR-T cells infusion. Infusion doses: The planned infusion doses are as follows: the first dose group at 1×10\^5 cells/kg; the second dose group at 3×10\^5 cells/kg; the third dose group at 1×10\^6 cells/ kg. Infusion doses refer to the number of CAR-positive cells.
Biological: FIT-(BCMA+CD19)-CAR-T Cells
Before cell infusion, researchers may decide, based on necessity, whether to administer prophylactic medication, which may include options such as acetaminophen and diphenhydramine, or H1 antihistamines, among others. Subjects are allowed to receive adequate supportive care after FIT-(BCMA+CD19)-CAR-T cells infusion, including blood transfusions and blood products, antibiotic therapy, antiemetics, antidiarrheals, analgesics, etc.
Incidence of dose-limiting toxicity
The proportion of patients receiving CAR-T cells who encounter dose-limiting toxicities (DLTs). Safety evaluations are performed in accordance with the NCI-CTCAE version 5.0 standards (Cytokine Release Syndrome and neurotoxicity will be graded based on ASTCT/ASBMT grading criteria).
Time frame: Up to 28 days from CAR-T infusion
Plan to share: No
No publications or documents are linked to this record.
Ran from Sep 2025 to primary completion in Nov 2025, 1 month.
Completion moved once since we started tracking on Sep 25, 2026: Nov 2041 → Apr 2026, on Oct 15, 2026.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
No participants
No participants
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is withdrawn, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Beijing Boren Hospital